Company intelligence / Profile preview
LamKap Bio gamma
Wollerau, Schwyz, Switzerlandlamkapbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
LamKap Bio gamma is a clinical-stage biotechnology company focused on the development of novel immunotherapies for hematologic malignancies. The company's lead program is a bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3, designed to redirect T-cells to eliminate malignant plasma cells in patients with multiple myeloma. As part of the LamKap Bio group, the company operates as a focused entity to advance specific therapeutic assets through early clinical development. Its primary mission is to address unmet medical needs in oncology through precision-engineered antibody therapies.
- Therapeutic areas
- Oncology
- Modalities
- Bispecific monoclonal antibodyMonoclonal antibody
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on LamKap Bio gamma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LamKap Bio gamma.